サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757799

経鼻ワクチンの世界市場

Nasal Vaccines

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.70円
経鼻ワクチンの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

経鼻ワクチンの世界市場は2030年までに6億6,530万米ドルに達する見込み

2024年に4億3,940万米ドルと推定される経鼻ワクチンの世界市場は、2024～2030年の分析期間にCAGR 7.2%で成長し、2030年には6億6,530万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである弱毒生ワクチンは、CAGR 9.3%を記録し、分析期間終了時には1億9,050万米ドルに達すると予測されます。不活化ワクチン分野の成長率は、分析期間中CAGR 8.8%と推定されます。

米国市場は1億1,970万米ドルと推定、中国はCAGR 11.5％で成長予測

米国の経鼻ワクチン市場は、2024年に1億1,970万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億4,210万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と7.0%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の経鼻ワクチン市場- 主要動向と促進要因のまとめ

なぜ経鼻ワクチンは予防接種戦略で勢いを増しているのか？

経鼻ワクチンは、自然な感染経路を模倣した、針を使わない粘膜ベースの予防接種を提供し、ワクチンデリバリーシステムにおける革新的な進歩として、ますます認識されるようになっています。全身免疫を刺激する注射ワクチンとは異なり、経鼻ワクチンは多くの呼吸器病原体の主要な侵入口である粘膜表面を標的とし、全身免疫と局所免疫の両方を誘導します。この二重の反応により、予防効果を高めるだけでなく、ウイルスの排出や感染を減少させることができ、経鼻ワクチンは感染症の流行時に特に有用です。

特に小児や注射針恐怖症の人々における投与が容易であるため、集団予防接種のロジスティクスが再構築されつつあります。点鼻薬は訓練された人員や注射器を必要としないため、低資源環境での配布が簡素化されます。このような特徴により、特に迅速かつ大規模な予防接種が重要となるインフルエンザ、COVID-19、呼吸器合胞体ウイルス（RSV）などの疾患に対する世界の関心が高まっています。自己投与の可能性と、注射針に伴うバイオハザード廃棄物の排除は、このプラットフォームの公衆衛生上の価値をさらに強調しています。

どのような科学的進歩が経鼻ワクチンの有効性と安定性を高めているか？

製剤科学と送達技術における大きな革新が、経鼻ワクチンの開発を後押ししています。主要な進歩の一つは、鼻腔内での抗原の保持を強化し、より強く、より長く持続する免疫反応をもたらす、新しいアジュバントと粘接着性キャリアの使用です。リポソーム、ナノエマルジョン、ポリマーベースのデリバリーシステムは、抗原を分解から守ると同時に、粘膜免疫の誘導部位である鼻関連リンパ組織（NALT）による取り込みを促進するように設計されています。

耐熱性はもう一つの進歩分野であり、研究者はコールドチェーンロジスティクスの必要性を回避し、常温で保存可能なドライパウダーを開発しています。この特性は、遠隔地や過疎地での展開に特に重要です。さらに、組換えタンパク質サブユニットやウイルスベクターは経鼻用に調整されつつあり、より広範な抗原発現プロファイルや多価ターゲティングを提供しています。これらの進歩が相まって、経鼻ワクチンはより強固で汎用性が高く、幅広い病原体に対応できるようになっています。

最終用途と公衆衛生戦略はどのように拡大していますか？

経鼻ワクチンの最終用途は急速に進化しており、国の予防接種スケジュール、学校ベースのワクチンプログラム、パンデミック対策戦略への統合が進んでいます。小児や老人は呼吸器系疾患にかかりやすく、注射針による予防接種が難しいため、重要なターゲットグループとなっています。さらに、経鼻ワクチンは点滴の必要なく投与できるため、緊急時やアウトブレイク時の現場での使用に非常に適しています。

感染症だけでなく、アレルギー、アルツハイマー病、がん免疫療法などの非感染症への応用も研究が進んでいます。鼻から嗅球を経由して中枢神経系に直接アクセスできる鼻腔ルートは、神経学的および全身的な免疫調節のための魅力的な入り口となっています。政府や民間企業との共同研究は、医療上の解決策としてだけでなく、ワクチンの受容性を高め、ヘルスケアシステムの負担を軽減し、アウトブレイクへの対応を加速するための戦略的ツールとして、経鼻免疫の研究をますます進めています。

経鼻ワクチン市場の成長を促進する要因とは？

経鼻ワクチン市場の成長は、デリバリー・プラットフォームの進歩、対象疾患プロファイルの拡大、予防接種インフラのシステムシフトに関連するいくつかの要因によって牽引されています。特に、小児や高齢者、注射針を嫌う人々の間で、患者のコンプライアンスを向上させる注射針を使わないワクチンオプションに対する需要が高まっていることが主な要因の1つです。このような需要は、投与が容易で最小限の訓練で済むため、ロジスティクスの複雑さが軽減される集団予防接種の現場でさらに高まっています。

公衆衛生、旅行医療、小児医療、緊急発生対応など、最終用途の多様化により、経鼻ワクチンの商業的可能性が拡大しています。呼吸器疾患の罹患率の増加やパンデミックの脅威に対する世界の対策が、迅速でスケーラブルかつ非侵襲的なワクチン送達ソリューションに対する需要を促進しています。さらに、次世代ワクチン・プラットフォームに焦点を当てた規制当局の支援策や資金提供イニシアティブが、研究開発投資を促進し、臨床試験を加速させています。

製剤安定性、コールドチェーン非依存性、多抗原性といった技術的な向上も、経鼻ワクチンのバリュー・プロポジションを高めています。これらの特性は、従来の注射ワクチンが物流上の課題に直面している低資源環境や世界のワクチン接種構想にとって、特に魅力的なものとなっています。ヘルスケア、バイオテクノロジー、国際保健政策に関わる利害関係者が粘膜免疫の利点を共有することで、経鼻ワクチン市場は力強い成長と公衆衛生に大きな影響を与える態勢が整いつつあります。

セグメント

ワクチンタイプ（弱毒生ワクチン,不活化ワクチン,サブユニットワクチン,遺伝子組換えワクチン,混合ワクチン,その他のワクチンタイプ）;販売チャネル（公共,民間）

調査対象企業の例（全48件）

  • Altimmune, Inc.
  • AstraZeneca
  • Bharat Biotech
  • BioDiem Ltd
  • BioNTech SE
  • BlueWillow Biologics
  • Changchun BCHT Biotechnology Co.
  • Codagenix Inc.
  • CyanVac LLC
  • FluGen Inc.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • Intravacc
  • Meissa Vaccines Inc.
  • Ocugen, Inc.
  • Pfizer Inc.
  • Razi Vaccine and Serum Research Institute
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Vaxart, Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35409

Global Nasal Vaccines Market to Reach US$665.3 Million by 2030

The global market for Nasal Vaccines estimated at US$439.4 Million in the year 2024, is expected to reach US$665.3 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$190.5 Million by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$119.7 Million While China is Forecast to Grow at 11.5% CAGR

The Nasal Vaccines market in the U.S. is estimated at US$119.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$142.1 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Nasal Vaccines Market - Key Trends & Drivers Summarized

Why Are Nasal Vaccines Gaining Momentum in Immunization Strategies?

Nasal vaccines are increasingly recognized as a transformative advancement in vaccine delivery systems, offering needle-free, mucosal-based immunization that mimics natural infection pathways. Unlike injectable vaccines that stimulate systemic immunity, nasal vaccines target the mucosal surfaces-the primary entry points for many respiratory pathogens-thereby inducing both systemic and local immunity. This dual response not only improves protective efficacy but also reduces viral shedding and transmission, making nasal vaccines especially valuable during infectious disease outbreaks.

Their ease of administration, particularly in pediatric and needle-phobic populations, is reshaping mass vaccination logistics. Nasal sprays do not require trained personnel or syringes, simplifying distribution in low-resource settings. These features are driving increasing global interest, especially for diseases like influenza, COVID-19, and respiratory syncytial virus (RSV), where rapid, large-scale immunization is often critical. The potential for self-administration and the elimination of biohazardous waste associated with needles further underscore the public health value of this platform.

What Scientific Advances Are Enhancing the Efficacy and Stability of Nasal Vaccines?

Significant innovations in formulation science and delivery technology are boosting the development of nasal vaccines. One major advancement is the use of novel adjuvants and mucoadhesive carriers that enhance antigen retention in the nasal cavity, leading to stronger and longer-lasting immune responses. Liposomes, nanoemulsions, and polymer-based delivery systems are being engineered to protect antigens from degradation while promoting uptake by nasal-associated lymphoid tissue (NALT), the immune inductive site for mucosal immunity.

Thermostability is another area of progress, with researchers developing dry powder nasal vaccines that can be stored at ambient temperatures, bypassing the need for cold-chain logistics. This attribute is especially crucial for deployment in remote or underdeveloped regions. Additionally, recombinant protein subunits and viral vectors are being tailored for intranasal use, offering broader antigen expression profiles and multivalent targeting. Collectively, these advancements are making nasal vaccines more robust, versatile, and compatible with a wider range of pathogens.

How Are End-Use Applications and Public Health Strategies Expanding?

The end-use landscape for nasal vaccines is evolving rapidly, with increasing integration into national immunization schedules, school-based vaccine programs, and pandemic preparedness strategies. Pediatric and geriatric populations are emerging as key target groups due to their high susceptibility to respiratory diseases and the challenges they often face with needle-based vaccinations. Moreover, the ability to administer nasal vaccines without the need for intravenous access makes them highly suitable for use during emergencies and outbreaks in field conditions.

In addition to infectious diseases, research is expanding into nasal vaccines for non-communicable applications such as allergies, Alzheimer’s disease, and cancer immunotherapy. The nasal route provides direct access to the central nervous system via the olfactory bulb, making it an attractive portal for neurological and systemic immune modulation. Government and private-sector collaborations are increasingly exploring nasal immunization not only as a medical solution but as a strategic tool for boosting vaccine acceptance, reducing healthcare system burden, and accelerating outbreak response.

What Factors Are Driving Growth in the Nasal Vaccines Market?

The growth in the nasal vaccines market is driven by several factors tied to advancements in delivery platforms, expansion in target disease profiles, and systemic shifts in immunization infrastructure. One of the primary drivers is the rising demand for needle-free vaccine options that improve patient compliance, particularly among children, the elderly, and needle-averse individuals. This demand is further amplified in mass immunization settings where ease of administration and minimal training requirements reduce logistical complexity.

End-use diversification across public health, travel medicine, pediatric care, and emergency outbreak response is expanding the commercial viability of nasal vaccines. The increased incidence of respiratory illnesses and global preparedness efforts against pandemic threats are driving demand for rapid, scalable, and non-invasive vaccine delivery solutions. Additionally, supportive regulatory pathways and funding initiatives focused on next-generation vaccine platforms are catalyzing R&D investments and accelerating clinical trials.

Technological improvements in formulation stability, cold-chain independence, and multi-antigenic capability are also enhancing the value proposition of nasal vaccines. These attributes are making them particularly attractive for low-resource settings and global vaccination initiatives where traditional injectable vaccines face logistical challenges. As stakeholders across healthcare, biotechnology, and global health policy align around the benefits of mucosal immunization, the nasal vaccines market is poised for robust growth and significant public health impact.

SCOPE OF STUDY:

The report analyzes the Nasal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines, Other Vaccine Types); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Altimmune, Inc.
  • AstraZeneca
  • Bharat Biotech
  • BioDiem Ltd
  • BioNTech SE
  • BlueWillow Biologics
  • Changchun BCHT Biotechnology Co.
  • Codagenix Inc.
  • CyanVac LLC
  • FluGen Inc.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • Intravacc
  • Meissa Vaccines Inc.
  • Ocugen, Inc.
  • Pfizer Inc.
  • Razi Vaccine and Serum Research Institute
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Vaxart, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nasal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Mucosal Immunity Drives Research and Adoption of Intranasal Vaccine Platforms
    • OEM Development of Needle-Free Delivery Systems Supports Vaccine Acceptance in Pediatric and Geriatric Populations
    • Growth in Respiratory Disease Prevalence, Including COVID-19 and Influenza, Strengthens Use of Nasal Vaccines
    • Push for Self-Administered Vaccine Formats Enhances Market for Nasal Spray Formulations
    • Increasing Demand for Cold Chain-Free and Room Temperature-Stable Vaccines Promotes Innovation in Nasal Delivery
    • OEM Focus on Adjuvant Optimization and Mucoadhesive Formulations Improves Efficacy of Nasal Vaccines
    • Expansion of Nasal Vaccine Clinical Trials Across Infectious Diseases and Allergies Broadens Market Pipeline
    • Rising Government and NGO Investment in Pandemic Preparedness Supports Nasal Vaccine Infrastructure
    • Integration of Nasal Delivery With mRNA and Recombinant Platforms Fuels Next-Gen Vaccine Development
    • Global Vaccination Campaigns in Low-Income Regions Drive Demand for Easy-to-Use, Non-Invasive Formats
    • Push for Mass Immunization Tools That Reduce Needle Waste Supports Nasal Route Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nasal Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • JAPAN
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CHINA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • EUROPE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • FRANCE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • GERMANY
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SPAIN
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Spain 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Russia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AUSTRALIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Australia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • INDIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 80: India Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 82: India Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: India 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: South Korea 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • LATIN AMERICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Argentina 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • BRAZIL
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Brazil 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MEXICO
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Mexico 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MIDDLE EAST
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • IRAN
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Iran 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ISRAEL
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Israel 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UAE 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AFRICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Africa 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030

IV. COMPETITION